Bladder Cancer
Research activity in muscle-invasive bladder cancer centers on post-treatment disease control, with interest in immunotherapy strategies and outcomes after trimodality therapy.
- Durvalumab in bladder cancer
- Disease-free survival
- Adjuvant treatment
- Surveillance
The sponsor’s work in this area reflects a focus on integrating immune-based treatment approaches into the management of locally advanced bladder cancer.
Chronic Myelogenous Leukemia
In chronic myelogenous leukemia, the funded research is directed toward molecular response and treatment reinduction strategies involving tyrosine kinase inhibitor therapy.
- Ponatinib
- MMR status
- TKI reinduction
- Second treatment stop
This therapeutic area highlights sustained interest in long-term disease control and response monitoring in hematologic malignancy.
